Evergy Free cash flow increased by 7.7% to -$489.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 241.8%, from -$143.20M to -$489.40M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$170.20M | -$262.10M | -$259.60M | -$267.90M | -$227.70M | -$164.80M | -$224.20M | -$247.60M | -$301.30M | -$360.00M | -$118.60M | -$143.20M | -$303.40M | -$530.50M | -$489.40M |
| QoQ Change | — | -54.0% | +1.0% | -3.2% | +15.0% | +27.6% | -36.0% | -10.4% | -21.7% | -19.5% | +67.1% | -20.7% | -111.9% | -74.9% | +7.7% |
| YoY Change | — | — | — | -57.4% | +13.1% | +36.5% | +16.3% | -8.7% | -82.8% | -60.6% | +52.1% | +52.5% | +15.7% | -347.3% | -241.8% |